US panel set to vote on experimental Alzheimer's drug
Washington (AFP) - A US government expert committee was set to vote Friday on whether to recommend the approval of the first new Alzheimer's drug in almost two decades.The decisions reached by such panels, while nonbinding, are often accepted by the Food and Drug Administration. If it is eventually approved, Biogen's aducanumab would be the first drug ever to treat cognitive decline associated with Alzheimer's -- a major medical milestone.Some in the research community, however, say the evidence in favor of aducanumab is not yet clear-cut and more work needs to be done to prove it really works...